Peter O'Donnell, ACT's Brussels Correspondent

The tone of agency’s annual report contrasts its recent candid stance on regulatory vision for Europe

Media rebuke of Europe’s Innovative Medicines Initiative thrusts debate into the public arena.

In yet another demonstration of how far drug pricing concerns are invading the hitherto sacrosanct territory of drug development, a consortium of national advisory bodies on pricing have written to the chief official responsible for European Union drug research.

The European Medicines Agency's public consultation on yet another aspect of transparency on clinical trials data has elicited further critical comment about excessive official secrecy.

It seems only yesterday that the future for European pharma was personalized medicine. The European Union first gave the term official status in a formal paper in 2008, entitled a Renewed Vision for the Pharmaceutical Sector, in which the Commission included a section on ‘Towards more personalized medicines’.

While such discussions have advanced in Europe, two key omissions from the dialogue may limit any real changes.

How the European Union is impacting current Pharmaceutical trends.

Professor Sirpa Leppä pointed to the increasing challenge of inducing trial sponsors to select Finland in recent article.

The European Union's extensive transatlantic links have reached a further level of maturity with the completion at the end of 2014 of exchanges between the European Medicines Agency and Health Canada.

The entry into force of the new EU clinical trials regulation last June is really little more than a virtual event.

It's official. Europe is sick-and much of the sickness derives from its economic problems.

Patients in Europe have been increasingly vocal in their demands for engagement in drug development and regulatory processes-and they have been increasingly effective.

After nearly five years of argument, the European Union's proposal to update its transparency directive for medicines has been dropped.

The conclusions on vaccination that European Union health ministers adopted on December 1 contain several sound thoughts.

In a health policy world where competition for profile is tough, a vacuum at the top is a serious disadvantage.

My recent blog has been overtaken by history, with the departure of Guido Rasi from his post of Executive Director of the European Medicines Agency

Growing insistence on making healthcare more patient-centered is generating a new level of interest in helping patients to meet the expectations the new orthodoxy is creating.

So now we know who is to do what on health issues in the new European Commission. Or do we?

What can be gleaned about the direction that health policy will take for the next five years under the new European Commission, scheduled to take office at the beginning of November?

It is a tragic truism to remark that the merits of the pharma sector are most sharply perceived only at times of deep human suffering.

New phase of innovation initiative emphasizes focus on research networks, adaptive trials, and personalized medicine, among other key areas.

As Europe departs for its annual holiday the question remains unresolved as to what to expect from the new European Parliament in terms of the principal interest of readers of Applied Clinical Trials.

The European Union's struggle to bring its data protection rules into the 21st century continues...

The European Union has managed to snatch defeat from the jaws of opportunity once more!

As the new European Parliament assembles for the start of its five-year term on July 1, many familiar faces will be missing.

Amid all the heated discussions of transparency and the insistence on ever wider disclosure, an intriguing contrast is provided by a document signed by health ministers on June 20.

A European bid to impose additional limits on research involving human embryos has been defeated.

EMA's crowning achievement in transparency?proactive release of clinical trials data?is only weeks from finalization.

The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry, but it is also revealing some remarkable displays of parochialism.

The European Medicines Agency is determined to minimize opposition to its next moves on releasing clinical trial data.